PharmaCyte Biotech Inc., a biotechnology company focused on cellular therapies for cancer, released its annual report for the fiscal year ending April 30, 2025. The company reported no revenues for the fiscal years 2025 and 2024. Operating expenses totaled $4.38 million for the year ended April 30, 2025, marking a decrease of $4.14 million compared to the previous year. This reduction was primarily due to lower compensation, director fees, and legal and professional expenses, although research and development (R&D) expenses increased by $30,985 to $438,416. This rise in R&D spending was attributed to a new agreement with consultants to conduct further research into pancreatic cancer treatment. The company highlighted its efforts to prepare for a planned clinical trial in locally advanced pancreatic cancer (LAPC). Looking ahead, PharmaCyte Biotech stated that its current cash reserves are expected to cover operating expenses for at least the next 12 months.